-
China Issues New Ethical Review Measures for Life Sciences and Medical Research
•
The National Health Commission, Ministry of Education, Ministry of Science and Technology, and National Administration of Traditional Chinese Medicine have released the “Measures for Ethical Review of Human Life Sciences and Medical Research.” This document establishes comprehensive guidelines to ensure ethical standards are met in all life science and medical…
-
Bayer Reports 2022 Sales Growth, Highlights New Drug Performances
•
Germany-based Bayer (ETR: BAYN) released its 2022 annual report this week, revealing a global sales growth of 8.7% year-on-year (YOY) in constant exchange rate and portfolio-adjusted terms, reaching EUR 50.7 billion (USD 53.8 billion). The report highlights significant performances across its business segments, particularly in Pharmaceuticals and Consumer Health. Pharmaceuticals…
-
China’s NRDL Update and Expansion of ‘Dual Channel’ Drug Access
•
The latest update to China’s National Reimbursement Drug List (NRDL) was implemented from March 1, 2023. Alongside this, Shanghai released a list of 383 drugs that will be involved in the “dual channel” management system. This initiative allows insured patients in Shanghai to purchase these drugs at designated retail pharmacies…
-
China’s State Council Unveils Plan for TCM Revitalization and Development
•
The State Council has released the “Traditional Chinese Medicine (TCM) Revitalization and Development Major Projects Implementation Plan.” This comprehensive document outlines a strategic approach to enhance the role of TCM in China’s health, economic, scientific, technological, cultural, and ecological landscape. TCM’s Strategic ImportanceThe document emphasizes that TCM is a vital…
-
Topchoice Medical to Acquire 19% Stake in Heren Health for $72.2M
•
China-based Topchoice Medical Investment Corp., (SHA: 600763) a leading medical service group, is set to acquire a 19% stake in compatriot firm Heren Health Co., Ltd, a smart medicine solutions provider for hospitals and governments. The transaction is valued at RMB 501 million (USD 72.2 million). The aim is to…
-
Eluminex Biosciences Closes $40M Series B for Ophthalmic Innovations
•
China-based ophthalmic biotech Eluminex Biosciences (Suzhou) Ltd has announced the closure of a Series B financing round, raising over USD 40 million. The funds will be directed towards clinical studies in biosynthetic cornea and the development of several innovative ophthalmic drugs. The financing round was led by Cenova Ventures, with…
-
RinuaGene Raises $14.4M in Pre-Series A+ for mRNA Drug Development
•
RinuaGene, an mRNA-based drug developer based in Suzhou, has reportedly raised close to RMB 100 million (USD 14.4 million) in a Pre-Series A+ financing round. The round was led by Dr. Jiang Guangce, chairman of DeChuan Investment, with participation from Truking, K2 Venture Partners, and Chang’An Capital, among others. The…
-
Junshi Biosciences Reports 2022 Preliminary Earnings with Revenue Decline
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has released its 2022 preliminary earnings estimate, indicating RMB 1.45 billion (USD 209.57 million) in revenues, down 63.89% year-on-year (YOY). The significant decline in revenues is attributed to the loss of licensing income and royalties from the COVID-19 antibody etesevimab (JS016/LY-CoV016), which was…
